Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04791488

Impact of Hyperoxia and Involvement of the Immune System in Diving Accident

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
265 (estimated)
Sponsor
Direction Centrale du Service de Santé des Armées · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The impact of oxygen therapy in many pathologies has been subject of recent work, arguing both favourable and harmful effects. Consequently, one can wonder about the influence of hyperoxic gas mixture during diving on the genesis of decompression sickness, but also about the systematic application of normobaric and hyperbaric oxygen in case of proven decompression sickness. In mammals, normoxic concentrations have been redefined at 20-100 mbars at the extracellular level and below 10 mbars in the mitochondria. Under hyperbaric conditions, most of the oxygen being dissolved in blood plasma, a state of hyperoxia is established which escapes the usual delivery and regulation system represented by red blood cells. The results of our team's previous work suggest a specific effect of diving on the levels of circulating mitochondrial DNA (mtDNA), suggesting cellular destruction linked to hyperoxia/hyperbaria. In fact, our studies, carried out on both animals and human divers, have shown that diving accident leads to an increase in mtDNA levels and an immune reaction through the mobilisation of leukocytes. The main objective of this study is to compare the influence of oxygen partial pressure levels on the evolution of clinical and biological variables during hyperbaric oxygen therapy sessions in healthy versus injured divers.

Conditions

Interventions

TypeNameDescription
PROCEDUREHyperbaric oxygen therapyHyperbaric oxygen therapy protocol
PROCEDUREDiving simulationHyperbaric chamber diving simulation protocol

Timeline

Start date
2022-03-30
Primary completion
2028-03-30
Completion
2028-03-30
First posted
2021-03-10
Last updated
2023-04-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04791488. Inclusion in this directory is not an endorsement.